Equillium Inc - ESG Rating & Company Profile powered by AI
If you are employed by Equillium Inc and you would like to licence your ESG rating, please get in touch. The SDG score for Equillium Inc indicates its reporting of the UN Sustainable Development Goals. Scroll down to the end of the webpage for potential risks for Equillium Inc based on sector, location and size.
Equillium Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.8; made up of an environmental score of 6.0, social score of 2.7 and governance score of 5.7.
4.8
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 1082 | Respiratorius AB (publ) | 4.9 | High |
| 1082 | Shenzhen Chipscreen Biosciences Co Ltd | 4.9 | High |
| 1121 | Equillium Inc | 4.8 | High |
| 1121 | Heat Biologics Inc | 4.8 | High |
| 1121 | Curis Inc | 4.8 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Equillium Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Equillium Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Equillium Inc report the average age of the workforce?
Sign up for free to unlockDoes Equillium Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Equillium Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Equillium Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Equillium Inc offer flexible work?
Sign up for free to unlockDoes Equillium Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Equillium Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Equillium Inc conduct supply chain audits?
Sign up for free to unlockDoes Equillium Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Equillium Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Equillium Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Equillium Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Equillium Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Equillium Inc disclose water use targets?
Sign up for free to unlockDoes Equillium Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Equillium Inc have a product recall in the last two years?
Sign up for free to unlockDoes Equillium Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Equillium Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Equillium Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Equillium Inc disclose parental leave metrics?
Sign up for free to unlockDoes Equillium Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Equillium Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Equillium Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Equillium Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Equillium Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Equillium Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Equillium Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Equillium Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Equillium Inc disclose its waste policy?
Sign up for free to unlockDoes Equillium Inc report according to TCFD requirements?
Sign up for free to unlockDoes Equillium Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Equillium Inc disclose energy use targets?
Sign up for free to unlockDoes Equillium Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Equillium Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Equillium Inc
These potential risks are based on the size, segment and geographies of the company.
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.